TransMedics Group, Inc. (TMDX) Earnings Call Transcript & Summary

Okay. I'd just like to welcome everyone to the final session of the day here, Wednesday, at the JPMorgan Healthcare Conference. My name is Allen Gong. I'm a member of the medical supplies and devices here at JPMorgan. And it's my pleasure today to have some of the members of the TransMedics management team here on the call, with the CEO, Waleed Hassanein; CFO, Stephen Gordon; and CCO, Tamer Khayal. [Operator Instructions]. And I will be happy to ask any questions that come in right now or during the course of the prepared remarks. With that, I'll turn it over for -- to the team for any prepared remarks that they have.

Thank you, Allen. Good evening, everybody. I'm Waleed Hassanein, CEO of TransMedics. It's a privilege to be here and talking to you about TransMedics. Slide 2 shows our forward-looking statement. Let's jump in on Slide 3. For you who don't know who TransMedics is and what we do, we're a company that is laser-focused on transforming the standard of care for solid organ transplantation using our disruptive organ care technology platform. Our goal is to significantly increase the supply of organs for transplant and improve the post-transplant clinical outcomes. Organ transplantation is a very unique field of medicine, where all 3 stakeholders are highly incentivized and motivated by what TransMedics' mission is. From a patient perspective, transplant represents the best quality of life and the longest life expectancy for a patient with end-stage organ failure, the best quality of life. From a provider perspective, transplant represents the treatment of choice or the gold standard for treating end-stage organ failure. More -- equally as important, transplant represents a significant revenue opportunity for transplant programs. It's a very high DRG with a significant margin contribution of approximately 40%. From a payer's perspective, organ transplant represents the most cost-effective or most efficient treatment -- cost-efficient treatment of end-stage organ failure. These are very, very complicated, highly expensive, complicated disease conditions. So what are the challenges in the field that TransMedics is trying to address? There are 2 main challenges in the field of organ transplant. First, the need for more and more organs to be transplanted and demand for organ transplant has been growing for the past decade, yet the number of organ supply remains static. Two, even in the organ transplant procedures performed today, there's a significant post-transplant complications. I'm talking about complications that could end up costing the recipient their lives or even requiring a second organ transplant called primary graft dysfunction where you transplant an organ, it never functions. So what are the causes of these challenges and what is the main culprit for these challenges and how TransMedics is going to address that? For the past 40 years, organ transplantation has seen significant innovations in every aspect of the therapy, from the surgical procedure to management of the patient to pre- and postoperative care, including immunosuppressive management. However, one area of organ transplantation remain literally frozen in time since the dawn of organ transplant, which is organ preservation. It has been limited to cold static storage. basically taking an organ out of the donor body, chilling it and putting it on ice to suspend physiology, suspend life and move it from donor to recipient. This approach of cold storage, no matter how pretty you make it has 3 major fundamental limitations. First, once you stop oxygen supply and blood supply to the organ and you chill it down, you subject that organ to a time-dependent significant injury called ischemic damage. The longer the organ spends on ice, the higher the probability of this organ never functioning for transplant and organ suffering from irreparable damage. Two, because the organ is literally just sitting on ice like a 6-pack or a steak, a piece of steak, there's no way of optimizing organ condition or functionality. And more importantly, there's no way of assessing the organ viability for transplantation. So we're simply stated, we're flying blind. These 3 limitations are the main reason why we use only 2 to 3 out of every 10 available heart and lung donors, wasting 7 to 8 out of every 10 donated organs on an annualized basis, significantly underutilizing the available donor pool. It is the main reason why we don't use a large pool of donors called DCD donors, or donor after circulatory death, because we can't assess their viability. And it's -- they are the same reasons why post-transplant complications remain to this day and age to a high rate of anywhere between 30% and 35%. The Organ Care System addresses these 3 limitations in a comprehensive fashion. First, in the Organ Care System, the organs are never subjected to ischemic damage because the organ is perfused with warm oxygenated and nutrients-enriched blood. The organ is alive. Physiology is active, so we can optimize the organ condition from the dying environment of brain death. And finally, because the organ is functioning, the heart is beating, the lung is breathing, the liver is producing bile, the kidney is making urine, we can fully assess organ viability up to the minute we're ready to transplant this organ. None of this could be achieved with any cold static preservation or even cold perfusion technology. The only way you can achieve this normal physiology is through a system like the Organ Care System, and we'll share with you some of the evidence we've built to date. Based on this technology, we will show you that we've demonstrated unequivocally that we can significantly increase the utilization of donor organs, both from donor after brain death and DCD donors or donors after circulatory death. Frankly, we're associated with the highest rate of utilization ever recorded in the history of organ transplant. We will also show you our post-transplant outcome improvement that we've achieved in our pivotal trials. First, Slide 7 shows you the different organ technology platforms. We're the only technology available today that has a multi-organ -- that is a multi-organ platform. We're not only focused on one organ. We're tackling the largest -- the 4 largest organs in transplantation: heart, lung and liver. And next year, we are expanding into kidney transplant. As you see on Slide 7, you see that we have a capital equipment, and we have a disposable component. The 99% of our revenue comes from the sales of the disposables, not -- capital equipment is a onetime sale. Let's share with you some of the evidence that gives us the confidence and the foundation that we're building the business upon today. So through our large global evidence that we've collected over the years, we've done close to 2,000 transplants across all 3 organs. We've demonstrated in FDA Level 1 evidence pivotal trial that we have been able to move organ utilization in lung transplant from 23% using cold storage to nearly 90% or 87% to be exact using the Organ Care System technology. Meaning, we've taken 10 lungs that otherwise would have been thrown away, and we've made them transplanted at a rate of 9 out of every 10. Doing the same thing for the heart, we've taken heart utilization from 30% up to 80% or 81%. Again, taking 10 hearts that otherwise would have been thrown away, and we've made 8 out of the 10 transplant. But what excites us is we didn't stop there. We pushed the envelope even further where we tackled this larger pool of donors called DCD donors. 7 years ago, there was no such thing as a DCD heart transplant. Can you imagine taking a heart after a heart has stopped beating for 30 minutes, and you're taking that heart and transplanting it into a recipient suffering from heart failure? That never existed before the OCS. Today, it is the fastest-growing segment of heart transplant, DCD heart transplant. Using the Organ Care System, we were able to demonstrate unequivocally that we could take 10 DCD hearts after they've completely stopped beating for 30 minutes and make 9 out of those 10 fully resuscitated, fully reanimated, beating, functioning, tested and transplanted successfully. But we didn't stop there. We didn't just focus on improving utilization, but we also tackled and proven that with our technology, we can significantly improve post-transplant outcomes. We wanted to show that by reducing that ischemic damage or ischemic injury on the organ and better physiologic preservation devoid from cold and injury, we can improve post-transplant outcomes. And we've demonstrated that. In the lung, we've demonstrated that we can reduce primary graft dysfunction rate after lung transplant, which is the most severe form of complications that happen after lung transplantation by 50%. In the heart, we've demonstrated that we can reduce the same complication -- primary graft dysfunction in heart transplant by nearly 65%. And in the liver, we announced this data in 2020 that short term, we've reduced it by nearly 45% and long term, we've reduced complications related to the biliary complications by 84%. These are significant improvement in outcome that results in significant improvement in the financial profile of the transplant. But more importantly, the recipient is recovering quicker, is discharged from the hospital quicker and having much better quality of life. Let's talk a little bit about -- in Slide 10, discuss the organ transplant and donor retrieval market dynamic. Organ transplantation is very unique. It's an ultra-concentrated market, wherein the U.S., approximately 55 to 60 transplant centers derive approximately 70% of heart, lung and liver transplants across the U.S. Organ transplantation and organ retrieval for transplant is a very complex process that require donor surgical retrieval expertise, require a preservation and clinical expertise, logistics to include -- that includes organ procurement organization to match donors to recipients and the like. But more importantly, for the last 2 years, there has been a significant push -- federal push in the United States driven from CMS and HHS to increase the number of organ transplants. And there are metrics that has been proposed and passed into law in end of 2020 to apply pressure both on organ procurement organizations to improve the yield of donor organs for transplant, but also to motivate transplant programs to do more and more organ transplant. Slide 11 gives you a perspective of how many transplant programs are currently active with the Organ Care System technology, whether in our lung platform, which is commercial or the heart and liver platform, which is part of our clinical trial program. But then let's move forward and talk a little bit more about something that is very exciting for us, and it's something that's transforming the field, and we've been pioneering that for the last year. Let's talk a little bit about the dynamic of organ retrieval. And when you look at that, how organs are allocated and retrieved and managed, you'll find that there's this complex environment that is driven primarily, and the responsibility of that is lying primarily on the transplant center, where they are managing the recipient on their waiting list. They're responsible for performing their surgical procedure and managing the patient post-op. But importantly, that transplant program is the primary responsibility -- they're primarily responsible for also going out to where the donor is: managing the donor, retrieving the organ, preserving the organ and bringing it back. To use technologies like the OCS, transplant programs have to acquire the technology, have surgical expertise trained to use the technology, have clinical expertise trained to manage the organ on the technology and to be able to do that on a significantly higher rate because with the OCS, the utilization rate is significantly high. The OPO's role in this whole dynamic is nothing but to find a donor with -- secure the consent for donation and just allocating a donor -- a potential donor to a potential matching recipient. And they are under significant pressure, as we said, from CMS and HHS to increase the rate of utilized organ. When we saw that dynamic and in the early adoption of the lung commercial launch in 2020, we found this to be significantly complicated. And we saw that there's significant headwind related to transplant center logistics, logistical burden to how to integrate new technology and increase their rate of transplant at the same time. So for the last 6 to 9 months, we have developed and shifted our business model and accelerated the access to what we're calling the OCS National Service Program. And what the National Service Program that we've established in the U.S. means is TransMedics taking over the entire process of surgical retrieval, OCS management and assessment of the organ and transportation of that organ to their potential transplant center, working directly with the OPOs and having access to the donor hospital. But most importantly, maintaining our established relationship with the transplant program and allowing the transplant program to focus their resources, focus their expertise on the recipient management and the transplant procedure and the post-transplant patient care. There's no other -- we're well positioned, and we're in a very unique place. If you look at Slide 14, there's no other technology or company or entity that can do this. Our position is established based on our technology that is extremely unique and has the highest rate of utilization, and it's proven. Our clinical expertise that already exists in the company. We have a team -- our commercial team is 40-person strong, and they primarily are clinically driven individuals that knows how to operate the OCS and manage the OCS in their sleep. But also, our ability to alleviate the inertia and the logistical burden of the transplant program would enable them to rapidly adopt the technology, but more importantly, focus the resources in doing more transplant. Simply stated, the National Service Program allows TransMedics to take control of our own destiny, enable us to use the service angle to accelerate adoption of the technology and demonstrate the ability to increase the transplant volume without hampering the logistics of the transplant program. Let me give you an example of what we have done to date. Slide 15 shows you -- we started 2020 with one area where we started this National Service Program in Chicago. We ended the year in 6 regions in the United States, strategically located in the East Coast, South and the Southwest. Every one of these pink circles represent a region where there's OCS technology, there's OCS or TransMedics clinical staff and surgical staff, either contracted or full-time, that are readily 24/7 available to procure organs and move them to any lung transplant center in the United States. More importantly, we've established workflows that now -- that is organ-agnostic, meaning that once the heart is approved, once the liver is approved, we can immediately transition them into this National Service Program, enabling us to accelerate and improve or facilitate the adoption curve of these new and exciting markets. We are targeting to end 2021 at least doubling that regional coverage to -- our goal is over the next year to have strategically located these service hubs across the United States to ensure that we have maximum coverage for the major metropolitan areas. Slide 16 gives you a real-life cases that were done in Q3 and Q4 showing that we can move organs across continental U.S. without any issues. One of the benefits of doing that and demonstrating the ability to do that is we're no longer tied to a fixed number of centers that have bought the technology, have been trained in the technology. Using the National Service Program, we are now placing or allocating lungs across the United States. Any lung transplant program that wants TransMedics to procure and deliver organs for them is becoming an OCS program. It doesn't require all the different steps that we have with the direct acquisition business model. 2020, with all the hurdles and all the challenges that we've seen with COVID, was a year that we insisted that we lean forward, as I stated previously. Because one of the major limitations of -- during the COVID pandemic is many of these regions seen in Slide 15, many of these regions across the U.S. could not travel to procure organs. And we've seen the number of organ transplant plummet. With the establishment of the National Service Program, we told everybody, "Listen, we are here. We will bring you the organ to your doorsteps." And we have many examples, and I'm glad we leaned forward during this COVID pandemic to enable us to establish ourselves as a reliable partner to these transplant programs across the United States. Slide 17 really shows how excited we are about 2021 and many important catalysts that are coming our way. Starting in the hopefully first half of the year with 2 major FDA approvals that are lining up, one for the heart DBD indication that should be, hopefully, sometime in the early Q2 time frame, followed right after that with the liver DBD and DCD-approved indication sometimes in the late Q2 time frame. In the same time, we will have the readout of our DCD heart trial -- pivotal trial results and ending the year with the publications, both from the DCD and from the liver pivotal trial. So we're very excited about 2021. There's a lot of many important catalysts that will help us really accelerate our adoption of the OCS technology. When you look at our growth strategy, the near term is laser-focused on achieving these milestones and catalysts for 2021. The FDA approval and establish on growing our footprint in the national service model -- or National Service Program in the U.S. Mid-term is to expand our revenue across all 3 organs using the -- again, the National Service Program and direct acquisition, when applicable. And long term, we haven't forgotten about the kidney. We're initiating a kidney program pivotal trial end of 2021, beginning of 2022. And our international market will continue to deliver a good portion of our revenue, and we hope to see that grow long term by establishing more reimbursement mechanisms. When we look at our competitive landscape, we've erected many barriers. And now with the addition of the service program, we're really distancing ourselves from any just a technology that is focusing on either cold or warm preservation. We're really -- and I say that with a high degree of humility, we're in a league by ourselves. We have a global presence in the field of organ transplant. We have disruptive technology. We have a large robust pipeline of clinical indications. We're the only multi-organ platform and the clinical evidence speak for themselves. In addition, we have a very, very large IP portfolio that we really look at as the tip of the spear as far as competitive landscape. Let me end my presentation on Slide 20 by really giving you a forward-looking vision of where we look at ourselves as. We have no doubt that TransMedics will become the next standard of care in all solid organ transplant over the next 2 to 3 years. Our vision, our expectation is built on fundamentals that are proven. We have a disruptive technology that is first of its kind and with significant body of evidence proven the value of this technology. We've created a multibillion-dollar market opportunity that we are the ones that can satisfy. Our business model is disposable-driven. Even in the service environment, it's really about making more of our disposables being utilized. And we have the largest and most robust FDA pipeline from a clinical indication standpoint. And then finally, we have U.S. reimbursement already established, both from CMS and commercial payers. And we have great position of commercial and clinical footprint in major transplant institutions in the U.S. There's no doubt that over the next 3 or 4 years, we would not only will be the major platform for every organ transplant in this country, but more importantly, the only way we can double and triple transplant volumes in the U.S. and around the world is going to be on the Organ Care System. With that, I thank you so much for your time, and we will be open for questions.

Got it. Thank you so much for that, Waleed. So you guys have been public for 2 years now. And I would say that even with that amount of time kind of in the public eye, the market that you guys are looking at is a bit unique relative to what a traditional metric investor might really be looking at. So to start, and you kind of touched on this a little bit in your presentation, but when I think about like organ transplant for like lung failure or heart failure, these are obviously very sick patients, ones that I would generally classify as emergent. And one of the reasons why maybe these patients weren't being treated was because it's so hard to get physicians on the planes to go assess organs and then get the organ back to their sick patient at their actual transplant center. So when I think about that headwind and you saw that play out in second quarter and third quarter and really how COVID has played out in fourth quarter and still continues to be very relevant into one -- into the first quarter of 2021, how should we think about how TransMedics has been kind of weathering the headwind? And how should we think about, like to the extent that you can give it, you haven't provided guidance, the trajectory of your business over the course of fourth quarter and into first quarter?

Sure. Thank you, Allen. So all I can say, given that we didn't give any guidance and we didn't preannounce, is what we've expected and what we've discussed publicly on 2Q and 3Q calls, we expect that to materialize. Where we saw the biggest hit in Q2, we saw a recovery in Q3, and we expect to see a recovery in Q4. And again, barring significant resurgence of COVID that will paralyze and gum down the systems, I think we will continue to see recovery into Q1. I think for us, it's not -- it's not just COVID. So with COVID is one thing, but also we -- what gives us a little bit of hope is in Q1 that now we have the service model now firing on in 6 different regions. we're no longer just tied into one little region in Chicago, and that will help. So that's all I can comment on, Allen, and we'll be discussing the results for the full year and the Q4 here in a few weeks.

Got it. And just kind of just a clarification. So this is something where I think your business in kind of an unfortunate way is probably a little bit different, but some of your peers have benefited from a deferred procedure capture. And obviously, for your patients, these are incredibly sick patients. The -- my impression is that the potential for deferred procedure capture is probably quite low because of that. But to the extent that you might see a little bit of that, should we think of that as a potential benefit? Like where you have first half of the year, you're still really seeing lower travel, seeing lower transplant, but then we have a little bit more than normal in the back half of the year with some deferred procedures.

I can -- you're -- I can be more granular than we actually -- we expected to see some deferred volume capture in transplant. And we think that we're going to be in that position. More importantly than just deferred -- same number of patients who are in the waiting list to just be transplanted later. I think we've always suspected that, and I think it's becoming more and more publicized that many of the patients, especially younger patients that suffered from COVID may be added to the pool of patients that are requiring lung transplants. And now we're watching carefully any cardiac -- latent cardiac complications. So again, we don't wish that to be the case for everybody who had COVID, but definitely, we're seeing and hearing more and more lung transplants for COVID patients. That their lung completely deteriorated during the peak -- the initial peak and requiring lung transplantation for them after recovery.

So I think I'm not alone in saying that like kind of one of the most exciting initiatives for you guys really is this transition to the national service model and kind of becoming like more of -- like taking a bigger role in the actual organ transplant paradigm. So the last we heard from you on the third quarter is that you guys had started the program and now you're saying that you've really expanded it quite significantly. So based on the early experience that you've seen so far, taking into account the fact that volumes still remain probably a bit lower than you would normally see, what has really been the reception, right? Like what are the positives that you're really hearing from physicians from transplant centers? And if you're hearing any like when you go to these hospitals and transplant centers for the first time when you go to -- when you talk to the OPOs, what's really the pushback?

Allen, the -- let me start with the second part of the question. The only pushback is people needed to know what exactly are we talking about. There was a little bit of -- as any brand-new initiative, there's a lot of -- lack of full understanding of what do they expect. I think Tamer and the team did a phenomenal job throughout Q3 and Q4 to really educate the community, the lung transplant community, the OPO community. And frankly, we're beginning to do that for heart and liver now 6 months before approval. And with the successful cases, with the regional cases happening, for example, 1 metropolitan area, there's 2 major dominant transplant competing transplant programs. One used 3 lungs in 1 month. And the other, they're all through the service model. So what that competitive dynamic creates is that second center is coming to us saying, "Listen, I want to be a part of this." And understanding what -- how beneficial this is to them, how much this makes sense to them was very important. And it was primarily by our team educating the transplant community about what the potential benefit of that service model is. So that's one aspect. The second aspect is this national initiative or mandate by CMS for OPOs to increase their yield. So OPOs are under the gun now. They have 3 years to really be in the top 75th percentile, otherwise, they would lose their license for CMS coverage. So OPOs are looking for better ways to increase the yield, and there's no technologies that can do that without the OCS. So a combination of us describing what the value is to the transplant program, which is the key. That's the key driver still. OPOs are really a partner to us because we can access broader donor community and also make them transplant more organs. So it's the spread of the good cases, the experience and OPOs talking to OPOs about, yes, we transplanted 6 lungs last month or last quarter that we wouldn't have transplanted at -- so that word of mouth goes out. And from a transplant program, understanding the value for them and once that's done, we're really not seeing a lot of naysayer. It's just anything new, and we don't take anything for granted. We just need to continue to educate. And we've learned that we're not going to wait for FDA approval to start educating the heart-liver community. We're doing that today.

So that all sounds really exciting, but I'm going to ask -- I'm going to follow that up with, unfortunately, for better or for worse, what people really want to hear is like so you have this great National Service Program. What does that mean for your revenues? What does that mean for your costs? So should we think of this as really like an accelerant for adoption for lung and heart? Because by becoming the middleman, by becoming a better partner to the transplant center, they're going to be more willing to lean on you and really leverage OCS for their transplants? And then on the cost side, right, intuitively to me, it sounds like you're hiring essentially physicians who are going to be kind of doing a bit of the work to help assess the organ. And obviously, you're going to be paying for the equivalent of plane tickets, right, for these organs. So how should we think about the effect that will have on your cost profile? And ultimately, like as you move to become even more focused on leveraging this national service model, what will your ultimate cost profile look like? Because that does sound like it would be an incremental cost relative to just the status quo.

Sure. So let me address the second part first because it's a slight of a misunderstanding. We're not spending money on planes or plane tickets. All that is the cost of -- all the logistical cost is directly billed to the transplant program as it's being done today. So we're not a middleman in plane tickets. We're just using the same system that the transplant program uses and they bill the transplant center directly. What we -- the way we're pricing the service model is very straightforward. We have actually communicated to all transplant program in the U.S. that you're paying us X for the direct acquisition. For the national service model, you're paying us the same X for the cost of the technology. And in addition, you're adding Y in the form of the service component of our revenue. So from a cost perspective to us, the people who are regionally located, yes, we're going to increase the headcount, but it's not like doubling the headcount. We're increasing the headcount by about 20% or 30% because we started with a robust base that is nationally located across different regions. We're just filling in the gaps. And in certain active areas, we're doubling up the team. As far as the surgical expertise, we're not -- we don't have time to hire full-time surgeons. We have a national -- we created a national network of academic transplant surgeons in all major metropolitan regions in the United States on a contract basis. And we're using people that are well-known in the industry. They are peers to others. Again, the focus of this program is quality. We have to maintain the quality, maintain the same level of clinical expertise to build that program. Now let me go back to your early point, Allen, which is what does that do to our revenue. We wouldn't be doing it if we don't believe that this is not just an accelerant for the lung and getting the lung back on track, but we really believe that this National Service Program is going to facilitate and really improve the rate of adoption for heart and liver. And that's why I'm saying we're starting now even before the FDA approval, the education process. So once we have FDA approval, we -- it will become as close as plug and play as we can possibly have it. And we've always said that publicly last year that we have to be patient to get the workflows established, get ourselves established, get the relationship established because it's a foundational program once we have heart and liver will be added and hopefully kidney in the future. So yes, the answer is absolutely yes. We wouldn't be that excited about the National Service Program if it wasn't for significantly to grow our revenue and to grow our disposable revenue, not service revenue. Does that make sense?

Yes. No, definitely. So I guess like talking about like the near-term catalysts. Obviously, OCS Heart is one of the biggest ones for you in the near term that just through the trial revenues alone, I think that product has been doing very well for you. And unfortunately, because of COVID, the panel has been kind of pushed back a little bit. So once we have the panel, hopefully, in first quarter, but once you get that panel done, once you get the approval in the first half of the year, how should we really think about the adoption curve? When lung moved from trial to commercial, there was a little bit of bumpiness while you've got that transition squared away. So what are the kind of lessons you've learned? And how are you going to apply that to the heart launch?

Allen, it's everything we've been talking about. Everything we talk about is really lessons learned from the initial bumpiness on the lung. We need to remind you and the listeners that one of the main reasons in the bumpiness in the lung is we -- it was our first approval. We didn't have any CAP programs running. We literally finished the pivotal trial, and we disappeared for 14 or 18 months to get the approvals, and we didn't have any clinical activities in the U.S. So when we came back after the approval, it was like starting the discussion from scratch. So that's the first hurdle that really created a huge gap in the lung and huge headwind in the lung. The heart -- as you know, we have active CAP programs in both DBD and DCD. So that's one aspect. The second aspect is look at the number of centers that are active with OCS heart today, 25 U.S. centers. When we started with the lung approval, there was only 7. So that's another areas of optimism. And the third one and the big one for me personally and for us, TransMedics team, is the service model. Lung and heart transplanters are very close to each other. And in many cases, they're almost the same team. So seeing what's happening with the national service model and how we have demonstrated success with the lung would help tremendously with the heart. And by the way, we think that's going to happen for the liver as well. And the liver, we also have a CAP ongoing, and we're talking about national service rolling into the liver program. So that's really what gives us a lot of hope and excitement about 2021 and exiting 2021 into 2022 and beyond.

Got it. So we are coming up to the end of the session. I know a few questions just came in. And unfortunately, we're not going to have time to get through them right now. But Waleed, I just want to thank you so much for your time today, and I want to thank everyone on the call for attending the conference. And I want to wish everyone a good evening. And I hope the rest of the week goes well for you all, too.

Great. Thank you, Allen. Thank you, everyone.